BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 15453120)

  • 1. [New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin].
    van 't Wout JW; Kuijper EJ; Verweij PE; Kullberg BJ
    Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1679-84. PubMed ID: 15453120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [symbol: see text]Caspofungin and [symbol: see text]voriconazole for fungal infections.
    Drug Ther Bull; 2004 Jan; 42(1):5-8. PubMed ID: 14768298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Systemic antifungal agents].
    Lumbreras C; Lizasoain M; Aguado JM
    Enferm Infecc Microbiol Clin; 2003; 21(7):366-79; quiz 380, 390. PubMed ID: 14525693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifungal agents in children.
    Steinbach WJ
    Pediatr Clin North Am; 2005 Jun; 52(3):895-915, viii. PubMed ID: 15925667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of newer antifungal therapies in clinical practice: what do the data tell us?
    Perfect JR
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):15-23. PubMed ID: 15651178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe Candida albicans panophthalmitis treated with all available and potentially effective antifungal drugs: fluconazole, liposomal amphotericin B, caspofungin, and voriconazole.
    Manfredi R; Sabbatani S
    Scand J Infect Dis; 2006; 38(10):950-1. PubMed ID: 17008248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal resistance: the clinical front.
    Perfect JR
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 13):15-22. PubMed ID: 15682590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Update on therapy of invasive mycoses in hematology and oncology].
    Maschmeyer G; Haas A; Böhme A
    Dtsch Med Wochenschr; 2005 Jun; 130(22):1381-4. PubMed ID: 15915381
    [No Abstract]   [Full Text] [Related]  

  • 9. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
    Almyroudis NG; Sutton DA; Fothergill AW; Rinaldi MG; Kusne S
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2587-90. PubMed ID: 17452481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination antifungal therapy: where are we now, and where are we going?
    Marr K
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):24-9. PubMed ID: 15651179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Danaher PJ
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675092
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis.
    Cesaro S; Toffolutti T; Messina C; Calore E; Alaggio R; Cusinato R; Pillon M; Zanesco L
    Eur J Haematol; 2004 Jul; 73(1):50-5. PubMed ID: 15182338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voriconazole for candidosis: an important addition?
    Graybill JR
    Lancet; 2005 Oct 22-28; 366(9495):1413-4. PubMed ID: 16243074
    [No Abstract]   [Full Text] [Related]  

  • 15. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on the use of antifungal agents.
    Martinez R
    J Bras Pneumol; 2006; 32(5):449-60. PubMed ID: 17268750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of invasive candidal infections: systematic review and meta-analysis.
    Gafter-Gvili A; Vidal L; Goldberg E; Leibovici L; Paul M
    Mayo Clin Proc; 2008 Sep; 83(9):1011-21. PubMed ID: 18775201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comment: caspofungin acetate for treatment of invasive fungal infections.
    Chan J
    Ann Pharmacother; 2003 Apr; 37(4):595. PubMed ID: 12659624
    [No Abstract]   [Full Text] [Related]  

  • 19. Caspofungin for the treatment of azole resistant candidemia in a premature infant.
    Smith PB; Steinbach WJ; Cotten CM; Schell WA; Perfect JR; Walsh TJ; Benjamin DK
    J Perinatol; 2007 Feb; 27(2):127-9. PubMed ID: 17262048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Economic evaluation of the treatment of systemic fungal infections in immunocompromised patients: the role of itraconazole].
    Colombo GL; Morlotti L; Serra G
    Recenti Prog Med; 2005 Sep; 96(9):416-23. PubMed ID: 16229321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.